Ascendis Pharma A/S announced that it will call all $575 million of its 2.25% convertible senior notes due 2028, with the redemption scheduled for May 6 2026. The company will pay cash at 100 % of principal plus accrued interest, removing the notes from its balance sheet and eliminating future interest expense and conversion risk.
The call was triggered by an indenture provision that allows redemption when the share price exceeds 130 % of the conversion price for at least 20 trading days. Ascendis’ equity performance has pushed the share price above that threshold, prompting the redemption. Noteholders have until May 4 to convert; otherwise they receive the cash payment.
By eliminating the convertible debt, Ascendis reduces its debt‑to‑equity ratio and frees cash that can be deployed toward product commercialization, research and development, or other strategic initiatives. The redemption strengthens the company’s financial position without diluting existing shareholders, though up to 3.64 million ordinary shares could be issued if noteholders convert.
The redemption aligns with Ascendis’ broader strategy to scale its commercial operations and transition its Nasdaq listing from ADSs to directly listed ordinary shares. The company has also announced a $120 million share repurchase program, underscoring its focus on improving capital structure and shareholder value.
Investors have expressed concern about potential dilution and capital‑structure adjustments, which has tempered enthusiasm for the announcement. Nonetheless, the move is expected to improve long‑term financial flexibility and support the company’s growth plans for its TransCon drug‑delivery platform and pipeline candidates such as YORVIPATH, SKYTROFA, and TransCon CNP.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.